Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rofecoxib vs Naproxen in Chinese Patients with Rheumatoid Arthritis
NCT00157872Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2004
- Primary completion
- Jul 2004
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of rofecoxib in rheumatoid arthritis (RA) (2 arms), sponsored by Merck & Co. Primary endpoints: Tender Joint Count, Swollen Joint Count and 2 more. Started Jan 2004; status: completed.
02
Drugs
rofecoxib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00157872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00157872.